Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27968972 | 0.88 | TSHR (0.54) | TSHRALDH1A1HSD17B10L3MBTL1CDC25B | |
| SCHEMBL27968857 | 0.87 | TSHR (0.58) | TSHRALDH1A1HSD17B10KMT2AL3MBTL1 | |
| SCHEMBL8262732 | 0.87 | NR4A2 (0.47) | TSHRALDH1A1HSD17B10KMT2AL3MBTL1 | |
| SCHEMBL27968870 | 0.87 | ALDH1A1 (0.50) | TSHRALDH1A1HSD17B10KMT2AL3MBTL1 | |
| SCHEMBL3820817 | 0.86 | CXCR5 (0.51) | TSHRALDH1A1HSD17B10KMT2AL3MBTL1 | |
| SCHEMBL27968967 | 0.86 | TSHR (0.53) | TSHRALDH1A1HSD17B10KMT2AL3MBTL1 | |
| SCHEMBL7378022 | 0.84 | L3MBTL1 (0.48) | TSHRALDH1A1HSD17B10L3MBTL1CDC25B | |
| SCHEMBL6695034 | 0.84 | TSHR (0.54) | TSHRALDH1A1HSD17B10KMT2AL3MBTL1 | |
| SCHEMBL31173665 | 0.83 | KMT2A (0.53) | TSHRALDH1A1HSD17B10KMT2AL3MBTL1 | |
| SCHEMBL9735541 | 0.83 | TSHR (0.61) | TSHRALDH1A1HSD17B10KMT2ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | TSHR 3168/4885ALDH1A1 1422/4885HSD17B10 749/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | TSHR 3168/4885ALDH1A1 1422/4885HSD17B10 749/4885 |
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | TSHR 3672/4885ALDH1A1 275/4885HSD17B10 2100/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | TSHR 4580/4885ALDH1A1 758/4885HSD17B10 4264/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | TSHR 2854/4885ALDH1A1 1565/4885HSD17B10 806/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | TSHR 3645/4885ALDH1A1 690/4885HSD17B10 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.